Myasthenia gravis due to anti-PD-1 treatment for an advanced colon cancer patient: a case report and literature review.
J Neurol
; 271(8): 5326-5332, 2024 Aug.
Article
de En
| MEDLINE
| ID: mdl-38864881
ABSTRACT
With the advancement of cancer treatment technologies, immunotherapy has begun to be widely utilized. Colon cancer is one of the most common types of cancer, with metastasis being a frequent occurrence in late-stage patients. Hence, immunotherapy, as an emerging and potentially effective treatment modality, merits exploration to enhance patient survival rates and clinical benefits. However, various immune-related adverse events cannot be entirely avoided. Myasthenia gravis induced by immunotherapy serves as a rare but potentially lethal adverse event, and it has been increasingly reported. Understanding the mechanisms of irAEs can aid in controlling the side effects induced by treatment. Here, we reported a case of myasthenia gravis occurring after anti-PD-1 therapy for late-stage colon cancer.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs du côlon
/
Inhibiteurs de points de contrôle immunitaires
/
Myasthénie
Limites:
Aged
/
Humans
/
Male
/
Middle aged
Langue:
En
Journal:
J Neurol
Année:
2024
Type de document:
Article
Pays d'affiliation:
Chine
Pays de publication:
ALEMANHA
/
ALEMANIA
/
DE
/
DEUSTCHLAND
/
GERMANY